Skip to content Skip to footer
Subscribe Now

NEWS

Gilead to Acquire Tubulis for ~$5B
Shots: Gilead has entered into a definitive agreement to acquire Tubulis, making it an ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation As per the deal, Gilead will acquire Tubulis for $3.15B upfront & ~$1.85B in contingent milestone payments; closing is expected in Q2’26 Acquisition will expand…
April 8, 2026
Biogen Collaborates with Alloy Therapeutics to Advance Antisense Therapeutics
Shots: Alloy Therapeutics has entered into a collaboration & license agreement with Biogen to advance antisense therapeutics against multiple undisclosed targets using Alloy’s AntiClastic ASO Platform As per the deal, Alloy will receive an upfront payment, along with additional milestone payments & tiered royalties on any products resulting from the collaboration The AntiClastic ASO platform…
April 7, 2026
Apotex Receives Health Canada Approval for Denoza (Biosimilars, Prolia) 
Shots:  Health Canada has approved Denoza (denosumab injection), a biosimilar version of Prolia  Denoza is approved for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture. It is also authorized for all other indications of the reference biologic, as detailed in the Product Monograph  Denoza will be available in a prefilled syringe format  Ref: Apotex | Image: Apotex | Press Release…
April 7, 2026
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B
Shots: Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno, expanding its endocrinology & rare disease portfolio As per the deal, Neurocrine will acquire Soleno for $53/share in cash, representing a total transaction equity value of $2.9B Acquisition will add Vykat XR (diazoxide choline) to Neurocrine's portfolio for the treatment of hyperphagia with Prader-Willi…
April 6, 2026
Load more